Molecular Partners AG (SWX:MOLN)

Market Cap	125.01M
Revenue (ttm)	4.97M
Net Income (ttm)	-54.04M
Shares Out	36.87M
EPS (ttm)	-1.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,654
Average Volume	28,222
Open	3.365
Previous Close	3.390
Day's Range	3.245 - 3.470
52-Week Range	2.700 - 9.500
Beta	0.61
RSI	48.69
Earnings Date	Aug 25, 2025

About Molecular Partners AG

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (D...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 159
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: MOLN

Financial Performance

In 2024, Molecular Partners AG's revenue was 4.97 million, a decrease of -29.38% compared to the previous year's 7.04 million. Losses were -54.04 million, -12.81% less than in 2023.